Japan has approved groundbreaking stem-cell therapies for Parkinson’s disease and severe heart failure, with treatments expected to reach patients within months, according to reports and pharmaceutical company announcements on Friday.
Parkinson’s Treatment: Amchepry
Sumitomo Pharma received approval to manufacture and sell Amchepry, a treatment that transplants stem cells into the brain to replace lost dopamine-producing cells in Parkinson’s patients.
The therapy received conditional and time-limited approval, allowing faster patient access under Japan’s accelerated regulatory system.
A trial led by Kyoto University included seven Parkinson’s patients aged 50 to 69, each receiving five or ten million cells implanted into both sides of the brain.
Over a two-year follow-up, no major adverse effects were reported, and four patients showed symptom improvement.
Heart Failure Treatment: ReHeart
Japan’s health ministry also approved ReHeart, developed by the medical startup Cuorips, which uses heart muscle sheets derived from stem cells to regenerate damaged heart tissue and improve blood flow.
Both treatments are based on induced pluripotent stem (iPS) cells, a Nobel Prize-winning technology by Shinya Yamanaka. iPS cells can transform into virtually any type of cell, offering enormous potential in regenerative medicine.
Rapid Rollout for Patients
Health Minister Kenichiro Ueno expressed optimism about the therapies’ impact, saying, “I hope this will bring relief to patients not only in Japan but around the world. We will promptly carry out all necessary procedures to ensure it reaches all patients without fail.”
The treatments could become the world’s first commercially available medical products using iPS cells, potentially reaching patients as early as this summer.
Parkinson’s Disease and Global Impact
Parkinson’s disease affects the motor system, causing tremors and difficulty with movement. Approximately 10 million people worldwide live with the disease, according to the Parkinson’s Foundation.
Current therapies can alleviate symptoms but cannot stop disease progression, highlighting the significance of stem-cell breakthroughs like Amchepry.
The approvals mark a major milestone in regenerative medicine, offering hope for patients with neurological and cardiovascular disorders and signaling a new era of iPS-cell-based therapies.
